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Abstract
Purpose: To develop a clinical staging system based on the PIRO concept (Predisposition, Infection, Response and Organ
dysfunction) for hospitalized patients with infection.
Methods: One year prospective cohort study of all hospitalized patients with infection (n = 1035), admitted into a large
tertiary care, university hospital. Variables associated with hospital mortality were selected using logistic regressions. Based
on the regression coefficients, a score for each PIRO component was developed and a classification tree was used to stratify
patients into four stages of increased risk of hospital mortality. The final clinical staging system was then validated using an
independent cohort (n = 186).
Results: Factors significantly associated with hospital mortality were N for Predisposition: age, sex, previous antibiotic
therapy, chronic hepatic disease, chronic hematologic disease, cancer, atherosclerosis and a Karnofsky index,70; N for
Insult/Infection: type of infection N for Response: abnormal temperature, tachypnea, hyperglycemia and severity of infection
and N for Organ dysfunction: hypotension and SOFA score$1. The area under the ROC curve (CI95%) for the combined PIRO
model as a predictor for mortality was 0.85 (0.82–0.88). Based on the scores for each of the PIRO components and on the
cut-offs estimated from the classification tree, patients were stratified into four stages of increased mortality rates: stage I:
#5%, stage II: 6–20%, stage III: 21–50% and stage IV: .50%. Finally, this new clinical staging system was studied in a
validation cohort, which provided similar results (0%, 9%, 31% and 67%, in each stage, respectively).
Conclusions: Based on the PIRO concept, a new clinical staging system was developed for hospitalized patients with
infection, allowing stratification into four stages of increased mortality, using the different scores obtained in Predisposition,
Response, Infection and Organ dysfunction. The proposed system will likely help to define inclusion criteria in clinical trials
as well as tailoring individual management plans for patients with infection.
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Introduction
According to the 2012 World Health Organization report,
infections are among the top three leading causes of death
worldwide [1]. Developing new therapies for sepsis has been
particularly challenging and the successive failures have been
attributed to the inclusion of a very heterogeneous group of
patients.
In 2001, the American College of Chest Physicians and the
Society of Critical Care Medicine convened a consensus panel,
where John Marshall et al [2]. suggested an approach of sepsis
similar to the TNM (tumor, nodes and metastases) staging system
[3], used for cancer patients both as a prognostic tool and for
individualizing therapy. This led to the PIRO concept, which
attempts to characterize sepsis across four components: P for
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‘Predisposition (P), I for ‘Insult/Infection (I), R for ‘Response (R)
and O for ‘Organ dysfunction (O) [2,4].
This challenging concept took some time before being adopted
by the scientific community and was only recently tested in the
clinical field. Different approaches have been published, a model
development [5,6] and a scoring system [7–9] solely for patients in
the intensive care unit (ICU) setting; a score for patients with
suspected infection admitted from the Emergency department [10]
and finally a study that developed a staging system [11] but solely
for patients with severe sepsis and not considering all the originally
proposed variables.
The need for a clinical staging system applicable to all
hospitalized patients with confirmed infection remained. This
would help stratifying patients at risk, assess criteria for specific
therapies, predict outcomes and assist in rational enrolment into
clinical studies.
The objective of this study was to develop a clinical staging
system based on the PIRO concept through a prospective cohort
study in a diverse population of patients with infection on hospital
admission or throughout their hospital stay. The derived clinical
staging system is validated in an independent cohort.
Patients and Methods
A prospective cohort study was conducted in a 600-bed tertiary
care university hospital over a 1-year period (1st June 2008 to 31th
May 2009). All adult (age$18 years) infected patients consecu-
tively admitted to the medical, surgical, nephrology or hematology
wards of the hospital, or to ICU were included in the first 24 hours
of the diagnosis of infection according to the CDC criteria [12].
The inclusion criteria did not include microbiological data in
order to obviate delay in study inclusion or retrospective data
collection for diagnosis confirmation.
The data collected included all variables defined in the extended
sepsis criteria [2] which were grouped according to each PIRO
component as follows.
1. Predisposing factors (‘P’) analyzed included: age, sex,
season of admission, previous antibiotic therapy (any antibiotic
administration with therapeutic intention in the previous month),
hospitalization in the previous year, previous instrumentation,
Karnofsky index [13] (a value lower than 70 means inability to
carry out normal activity or do active work) and premorbid
conditions. Chronic morbidities recorded were: immunosuppres-
sion (administration of chemotherapy, radiation therapy during 12
months prior to hospital admission or the equivalent of 0.2 mg/
Kg/day prednisolone for at least 3 months or 1 mg/Kg/day for a
week during 3 months prior to hospital admission or human
immunodeficiency virus infection), chronic hepatic disease [14],
chronic heart failure [14], chronic respiratory disease [14],
hematologic disease [15], cancer [15], chronic renal failure (if
there was need for chronic renal support or a history of chronic
renal insufficiency with a serum creatinine level over 2 mg/dl),
diabetes mellitus (if insulin therapy or oral anti-diabetic drugs were
required before the infection) and/or atherosclerosis (if there was a
previous history of transient ischemic attack, stroke, angina,
myocardial infarction or peripheral arterial disease).
2. Insult/Infection (‘I’) was characterized by: type of
infection, categorized as either community-acquired (CAI), if the
infection was detected within 48 hours of hospital admission in
patients who did not fulfill the criteria for a healthcare-associated
infection; healthcare associated (HCAI - using the same criteria
that Deborah Friedman used for healthcare associated blood-
stream infections regardless of the involved focus of infection) [16]
or hospital-acquired (HAI) [12]; focus of infection (categorized as
respiratory [12], urinary [12], intra-abdominal [12], or others);
microbiology documentation of infection; presence of bacteremia
(primary or secondary) [17] and pathogen identification, classified
by category (Gram negative, Gram positive, fungus or poly-
microbial).
3. Host Response variables (‘R’) included: abnormal
temperature (fever or hypothermia), tachypnea, tachycardia,
abnormal white blood cells count (leukocytosis, leucopenia),
altered consciousness, hyperglycemia in the absence of diabetes,
peripheral edema, high serum C-reactive protein and severity of
infection as defined in the 2001 SCCM/ESICM/ACCP/ATS/
SIS International Sepsis Definitions Conference (infection, sepsis,
severe sepsis or septic shock at presentation [2]).
4. Organ dysfunction (‘O’) was assessed by the following
variables: hypoxemia, hypotension, high serum lactate, renal
dysfunction, high bilirubin, low platelet count, ileus, coagulopathy
and total SOFA score [18].
A second cohort was established to validate the proposed
clinical staging system. Data for the validation cohort were
retrospectively collected and included all patients admitted to the
same wards between 1st December 2011 and 31st January 2012 as
the derivation cohort, using the same inclusion criteria.
The primary outcome of interest was on in-hospital
mortality. All patients had complete follow-up until hospital
discharge in both cohorts.
This study was approved by the institutional review board
(which includes the Ethics for Health Committee) of Hospital de
Santo Anto´nio, Oporto Hospital Centre, Portugal, and informed
Table 1. Demographic and clinical characteristics of patients in the derivation and validation cohorts.
Variables Derivation cohort (n=1035) Validation cohort (n=186) p- value
Age in years, mean (SD) 65 (20) 69 (17) 0.002*
Male sex, n (%) 506 (49) 109 (59) 0.015#
ICU patients 149 (14) 40 (22) 0.016#
SAPS II, mean (SD) 29 (13) 35 (15) ,0.003*
Total SOFA, median (IQR) 1 (0–3) 2 (1–4) ,0.001&
Hospital mortality, n (%) 138 (13) 34 (18) 0.085#
SD – standard deviation, IQR – interquartile range. SOFA – Sepsis-related Organ Failure Assessment
*Independent samples t-test,
#Pearson Cui-square Test;
&Independent samples median test.
doi:10.1371/journal.pone.0070806.t001
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Table 2. Association of variables of each of the four components of PIRO with hospital mortality using logistic regression.
Characteristics of the patients included in the study according to the four components of the PIRO concept.
Predisposition Total, n (%) Non-survivors, n (%) Crude OR p- value
Age ,0.001
#60 years 388 (38) 18 (5) 1.0
61–80 years 387 (37) 63 (16) 4.0
.80 years 260 (25) 57 (22) 5.8
Male sex, n (%) 506 (49) 79 (16) 1.5 0.036
Season
Spring, n (%) 260 (25) 25 (10) 1.0
Summer, n (%) 248 (24) 32 (13) 1.4 0.242
Autumn, n (%) 277 (27) 42 (15) 1.7 0.056
Winter, n (%) 249 (24) 39 (16) 1.7 0.041
Previous antibiotic therapy, n (%) 367 (36) 67 (18) 1.9 0.001
Hospitalization in the previous year, n (%) 413 (40) 65 (16) 1.4 0.064
Previous instrumentation, n (%) 373 (36) 67 (18) 1.8 0.001
Comorbidities, n (%) 671 (65) 108 (16) 2.1 ,0.001
Immunosupression, n (%) 221 (21) 24 (11) 0.7 0.224
Chronic hepatic disease, n (%) 22 (2) 8 (36) 3.9 0.003
Chronic renal disease, n (%) 69 (7) 3 (4) 0.3 0.023
Chronic heart failure, n (%) 74 (7) 12 (16) 1.3 0.450
Chronic respiratory disease, n (%) 66 (6) 10 (15) 1.2 0.654
Chronic haematologic disease, n (%) 60 (6) 17 (28) 2.8 0.001
Cancer, n (%) 45 (4) 18 (40) 4.8 ,0.001
Diabetes, n (%) 204 (20) 15 (7) 0.5 0.006
Atherosclerosis, n (%) 242 (23) 54 (22) 2.4 ,0.001
Karnovsky index,70, n (%) 319 (31) 81 (25) 3.9 ,0.001
Infection
Type of infection 0.001
Community-acquired, n (%) 493 (48) 47 (10) 1.0
Healthcare-associated, n (%) 225 (22) 32 (14) 1.6
Hospital-acquired, n (%) 316 (30) 59 (19) 2.2
Focus of infection 0.140
Respiratory, n (%) 419 (40) 63 (15) 1.0
Urinary, n (%) 344 (33) 35 (10) 0.6
Intra-abdominal, n (%) 213 (21) 29 (14) 0.9
Other, n (%) 59 (6) 11 (19) 1.3
Primary bacteraemia, n (%) 57 (6) 10 (17) 1.4 0.338
Secondary bacteraemia, n (%) 96 (9) 15 (16) 1.3 0.489
Microbiology isolation, n (%) 703 (68) 99 (14) 1.2 0.303
Positive blood cultures, n (%) 154 (15) 25 (16) 1.3 0.252
Type of microorganism, n(%) 0.406
Gram negative, n (%) 384 (55) 48 (12) 1.0
Gram positive, n (%) 204 (29) 34 (17) 1.4
Fungi, n (%) 15 (2) 1 (7) 0.5
Polymicrobial, n (%) 100 (14) 16 (16) 1.3 0.410
Response
Temperature 0.006
No alteration, n(%) 461 (45) 57 (12) 1.0
Fever, n (%) 336 (33) 35 (10) 0.8
Hypothermia, n (%) 238 (22) 46 (19) 1.7
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consent from the participants was waived due to its purely
observational nature.
Statistical Analysis
Continuous variables were described as means and standard
deviations (SD) or as medians and inter-quartile ranges (IQR) if
they showed a skewed distribution. Categorical variables were
described with absolute frequencies and percentages. Student T-
tests or Mann-Whitney tests were used to compare continuous
values between survivors and non-survivors. For categorical
variables, these comparisons were performed using Pearson x2
test.
To build the prediction models for P, I, R and O, variables with
marginal association with mortality in the univariate analysis (p
value ,0.2) were screened for the multivariate analysis. Four
separate logistic regression models - one for each component ‘‘P’’,
‘‘I’’, ‘‘R’’ and ‘‘O’’ – were built using stepwise selection on the
variables screened in the previous phase. Once the models were
fitted, four scores for each patient were computed, representing
the probability of death predicted by each model. The four scores
were combined into a logistic regression referred to as ‘‘combined
PIRO’’.
The results of the multivariable models are expressed as odds
ratio (OR) with 95% confidence interval (CI95%) and p-values.
The accuracy of the models was assessed by the area under
receiver operating characteristics curve (AU-ROC) and calibration
was tested using the Hosmer-Lemeshow goodness-of-fit test.
In order to simplify the computation of the scores for each
component, the regression coefficients were multiplied by two and
rounded to the nearest integer. This simplified scoring system was
then used to compare the scores obtained directly from the
derivation models with the non-rounded coefficients. The AU-
ROCs of the simplified version were identical to the derivation
ones.
After obtaining the new scores for each PIRO component, a
classification tree was used to define cut-offs for component score
and identify profiles of risk of death across the four PIRO
components. Each node split decision in the tree was chosen from
the possible cut-offs for all components, maximizing the within-
node homogeneity according to Gini’s coefficient [19] impurity
measure, which is known to be closely related to both, the AU-
ROC and the Mann-Whitney-U test [20].
A cross table with all possible profiles resulting from the
combination of Predisposition, Infection, Response and Organ
dysfunction against hospital outcome was built and analyzed to
yield the final algorithm. In order to simplify the presentation of
results, the profiles were further clustered into four clinical stages
according to the risk of death.
The significance level for all tests was defined as p,0.05. Data
were analyzed using SPSS, version 18 for Windows (Chicago, IL).
Table 2. Cont.
Predisposition Total, n (%) Non-survivors, n (%) Crude OR p- value
Tachypneia, n (%) 457 (44) 83 (18) 2.1 ,0.001
Tachycardia, n (%) 620 (60) 96 (15) 1.6 0.013
Reactive C protein.5 mg/dl, n (%) 923 (89) 126 (14) 1.3 0.389
White blood cells 0.360
No alteration, n (%) 425 (41) 56 (13) 1.0
Leucocytosis, n (%) 560 (54) 72 (13) 1.0
Leucopenia, n (%) 50 (5) 10 (20) 1.7
Altered conscious, n (%) 43 (4) 14 (33) 3.4 ,0.001
Hyperglycemia, n (%) 159 (15) 38 (24) 2.4 ,0.001
Severity of infection ,0.001
Infection, n (%) 281 (27) 20 (7) 1.0
Sepsis, n (%) 364 (35) 30 (8) 1.2
Severe sepsis, n (%) 296 (29) 46 (15) 2.4
Septic shock, n (%) 94 (9) 42 (45) 10.5
Organ dysfunction
Hypoxemia, n (%) 267 (26) 57 (21) 2.3 ,0.001
Hypotension, n (%) 175 (17) 63 (36) 5.9 ,0.001
Lactacidemia.1 mmol/L, n (%) 134 (13) 44 (33) 4.2 ,0.001
Creatinine.2 mg/dl or diuresis,0,5 ml/Kg/h, n (%) 136 (13) 32 (23) 2.3 ,0.001
Bilirubin.4 mg/dl, n (%) 20 (2) 5 (25) 2.2 0.131
Platelets,100.000, n (%) 96 (9) 26 (27) 2.7 ,0.001
Ileus, n (%) 5 (1) 3 (60) 9.9 0.012
Coagulopathy (INR.1.5 or aPTT.60 s), n (%) 8 (1) 4 (3) 6.7 0.008
SOFA.0 691 (67) 118 (17) 3.3 ,0.001
SOFA - Sepsis-related Organ Failure Assessment, OR – Odds ratio.
doi:10.1371/journal.pone.0070806.t002
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Results
During the study period, a total of 3733 patients were assessed
and 1035 (28%) met the inclusion criteria for having infection
according to the CDC definitions of infection and hence were
included in the study. Mean (SD) age was 65 (20) years and mean
SAPS II was 29 (13), overall hospital mortality rate was 13%
(table 1). The median hospital length of stay in the derivation
Table 3. Selection of variables significantly associated with hospital mortality using logistic regression, within each of the four
components of PIRO.
Variables Total, n(%) Non-survivors, n (%)
Regression
coefficients Adjusted OR CI95% p- value
Predisposition
Age
#60 years 388 (38) 18 (5) 1.0
61–80 years 387 (37) 63 (16) 0.7 2.0 1.5–2.7 ,0.001
.80 years 260 (25) 57 (22) 1.4 4.0 2.2–7.3 ,0.001
Male sex, n (%) 506 (49) 79 (16) 0.6 1.8 1.2–2.6 0.005
Previous antibiotic therapy, n (%) 367 (36) 67 (18) 0.7 1.9 1.3–2.9 0.001
Chronic hepatic disease, n (%) 22 (2) 8 (36) 1.9 7.0 2.5–19.0 ,0.001
Chronic haematologic disease, n (%) 60 (6) 17 (28) 1.5 4.3 2.2–8.5 ,0.001
Cancer, n (%) 45 (4) 18 (40) 1.7 5.6 2.8–11.1 ,0.001
Atherosclerosis, n (%) 242 (23) 54 (22) 0.5 1.6 1.0–2.4 0.050
Karnovsky index,70, n (%) 319 (31) 81 (25) 0.9 2.4 1.6–3.8 ,0.001
Infection
Community-acquired, n (%) 493 (48) 47 (10) 1.0
Healthcare-associated, n (%) 225 (22) 32 (14) 0.5 1.6 1.0–2.5 0.064
Hospital-acquired, n (%) 316 (30) 59 (19) 0.8 2.2 1.4–3.3 ,0.001
Response
Temperature
No alteration, n(%) 461 (45) 57 (12) 1.0
Fever, n (%) 336 (33) 35 (10) 20.4 0.7 0.4–1.1
Hypothermia, n (%) 238 (22) 46 (19) 0.3 1.4 0.9–2.1
Tachypneia, n (%) 457 (44) 83 (18) 0.4 1.5 1.0–2.3 0.049
Hyperglycemia, n (%) 159 (15) 38 (24) 0.6 1.7 1.1–2.8 0.016
Severity of infection
Infection or sepsis, n (%) 645 (62) 50 (8) 1.0
Severe sepsis, n (%) 296 (29) 46 (15) 0.7 1.9 1.2–3.0 0.005
Septic shock, n (%) 94 (9) 42 (45) 2.0 7.4 4.4–12.6 ,0.001
Organ dysfunction
Hypotension, n (%) 175 (17) 63 (36) 1.6 4.6 3.1–7.1 ,0.001
SOFA.0 691 (67) 118 (17) 0.7 2.0 1.2–3.4 0.009
SOFA – Sepsis-related Organ Failure Assessment, OR – odds ratio, CI – confidence interval.
doi:10.1371/journal.pone.0070806.t003
Table 4. Area under the receiver operating characteristics curve (95% Confidence Interval) of predicted probabilities by hospital
mortality of each PIRO component, the combined PIRO model and SAPS II, in the derivation and in the validation cohorts.
Predisposition Insult Response Organ PIRO SAPS II
Study population
(n = 1035)
0.79 (0.75–0.83) 0.59 (0.54–0.64) 0.72 (0.67–0.77) 0.71 (0.66–0.75) 0.85 (0.82–0.88) 0.81 (0.77–0.84)
Ward (n = 886) 0.84 (0.80–0.88) 0.61 (0.55–0.67) 0.66 (0.60–0.72) 0.66 (0.60–0.72) 0.84 (0.80–0.88) 0.78 (0.74–0.83)
ICU (n = 149) 0.77 (0.69–0.86) 0.50 (0.40–0.60) 0.79 (0.71–0.88) 0.70 (0.61–0.79) 0.83 (0.75–0.91) 0.83 (0.76–0.91)
Validation cohort
(n = 186)
0.75 (0.67–0.83) 0.60 (0.49–0.70) 0.73 (0.64–0.83) 0.77 (0.69–0.85) 0.84 (0.76–0.91) 0.85 (0.78–0.92)
doi:10.1371/journal.pone.0070806.t004
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cohort was 11 (7–22) days. A microbiological confirmation of
infection was available in 68% of patients (56% for CAI, 73% for
HCAI and 83% for HAI).The validation cohort included 186
patients that were significantly older, with a mean age of 69 (17)
years and a mean SAPS II of 35 (15) (table1).
In table 2, a detailed description of patients’ characteristics and
their association with hospital mortality, according to the four
components of PIRO, is shown. In table 3, variables indepen-
dently associated with hospital mortality according to each
component of the PIRO concept are described. Variables retained
in the final model for predisposing factors (‘‘P’’) included age,
gender, previous antibiotic therapy, chronic hepatic disease,
chronic hematologic disease, cancer, atherosclerosis and a
Karnofsky index ,70. For those characterizing infection, (‘‘I’’),
only the type of infection was retained. Response (‘‘R’’) variables
included abnormal temperature, tachypnea, hyperglycemia, and
the severity of infection. Organ dysfunction (‘‘O’’) was character-
ized by hypotension and a SOFA score $1.
The AU-ROC(CI95%) of predicted probabilities for hospital
mortality for each PIRO component and the combined PIRO
model, in the derivation and in the validation cohorts, are shown
in table 4. The combined PIRO model had an AU-ROC of
0.85(0.82–0.88) in the derivation cohort and 0.84 (0.76–0.91) in
the validation cohort. The Hosmer and Lemeshow test did not
show evidence for lack of fit in all four components or in the
combined model, be it in the derivation or in the validation
cohorts (p.0.1). Comparing this new PIRO model with SAPS II,
it shows a higher discrimination power, with an AU-ROC of 0.85
vs 0.81. The performance was also different according to different
settings: the PIRO score performed better in the ward with an
AU-ROC of 0.84 vs 0.78 of the SAPS II while in the ICU setting
both had a similar performance, AU-ROC=0.83 (table 4).
Using the rounded regression coefficients for each variable, a
weighted clinical classification rule was generated to yield the
PIRO scores for each component (table 5). Figure 1 shows the
‘‘Classification tree used to define cut-offs for each score and
identify clusters of risk of death in the derivation cohort’’, allowing
patients’ stratification in risk stages for each variable. Predisposi-
tion had three stages: P1(0–2 points), P2(3–4 points) and P3($5
points). Infection had two stages: I1(0–1 points) and I2(2 points).
Response had two stages: R1(0–3 points) and R2($4 points).
Organ dysfunction had two stages: O1(0 points) and O2($1
points).
Increasing stages were associated with an increase in hospital
mortality rate, both in the derivation and in the validation cohorts
(table 6). The expected mortality was then computed for all
possible PIRO combinations defining patients’ risk profiles (Table
S1 - Mortality rate and clinical stage according to patients’ PIRO
Figure 1. Classification tree used to define cut-offs for component score and identify profiles of risk of death in the derivation
cohort across the four PIRO components. Each node split decision in the tree was chosen from the possible cut-offs for all components,
maximizing the within-node homogeneity.
doi:10.1371/journal.pone.0070806.g001
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characteristics, in the derivation cohort). Using this table, the
profiles were clustered into four stages of increased risk for hospital
mortality (Table 7).
Stage I (defined as [P122 I122 R1 O1] or [P1 I1 R1 O2]) included
436 patients with low or medium predisposition, low response
score (without septic shock), and either no organ dysfunction,
regardless of place of acquisition, or with organ dysfunction but
without hospital-acquired infection. Patients in stage I had a
hospital mortality rate of 2% (CI95%, 0.4–3%).
Stage II ([P1 I1 R2 O2], [P1 I2 R1 O2],, [P2 I122 R1 O2] or [P3
I122 R1 O1]) included 354 patients with a low predisposition,
without hospital-acquired infection, but with a high response score
and organ dysfunction or low predisposition, with hospital-
acquired infection, low response (without septic shock) but with
organ dysfunction. This stage also included patients with medium
predisposition score with low response (no septic shock) and organ
dysfunction or high predisposition with low response and no organ
dysfunction. This group of patients had a hospital mortality rate of
11% (CI95%, 8–15%).
The 197 patients in stage III, ([P3 I1–2 R1 O2]) were patients
with high predisposition, low response and with organ dysfunction.
These patients had a hospital mortality rate of 31% (CI95%, 25–
37%).
Stage IV ([P2–3 I1–2 R2 O2]) included 42 patients with a medium
or high predisposition score, a high response and also organ
dysfunction, regardless of place of acquisition of infection. Their
hospital mortality rate was 71% (CI95%, 58–85%).
In the validation cohort, the mortality rate was 0% in stage I (0/
52), 9% in stage II (5/54), 31% in stage III (15/49) and 67% in
stage IV (6/9) (Table S2 - Mortality rate and clinical stage
according to patients PIRO characteristics, in the validation
cohort).
In figure 2 different stages of PIRO obtained according to the
different combinations of Predisposition (P1, P2, P3), Insult (I1,
I2), Response (R1, R2) and Organ dysfunction scores (O1, O2) are
shown.
Discussion
This study proposes a clinical staging system for patients with
infection based on the PIRO concept. It was developed and
validated in a large cohort of unselected hospitalized patients with
infection because most patients with infection are outside the ICU
setting (86% in our study), widening the clinical application of the
original concept proposed.
Comparing this new PIRO score with other prognostic scores,
namely SAPS II, it performed superiorly (0.85 vs 0.81) with a
Table 5. Scores attributed to the selected variables regarding each of the four components of PIRO.
P score Points I score Points R score Points O score Points
Age Type of infection Altered temperature Hypotension 3
#60 years 0 CAI 0 No 0 SOFA.0 1
61–80 1 HCAI 1 Fever 21
.80 3 HAI 2 Hypothermia 1
Male 1 Hyperglycemia 1
Previous ATB 1 Tachypneia 1
Chronic hepatic disease 4 Severity of infection
Chronic haematologic disease 3 Infection or sepsis 0
Cancer 3 Severe sepsis 1
Atherosclerosis 1 Septic shock 4
Karnovsky,70 2
TOTAL possible points 18 2 7 4
P score – Predisposition score, I score – Insult/Infection score, R score – Host Response score, O score – Organ dysfunction score, ATB – antibiotic therapy, CAI –
community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, SOFA – Sepsis-related Organ Failure Assessment.
doi:10.1371/journal.pone.0070806.t005
Table 6. Risk of hospital mortality according to the total score of each PIRO component.
Predisposition Insult Response Organ
Risk of mortality classification P1 Low P2 Medium P3 High I1 Low I2 High R1 Low R2 High O1 Low O2 High
Score (total sum of points) 0–2 3–4 $5 0–1 2 0–3 $4 0 $1
Derivation Cohort
Hospital mortality (n = 138) 3% 11% 30% 11% 19% 11% 47% 5% 17%
Percentage of total patients (n = 1035) 45% 25% 30% 69% 31% 93% 7% 33% 67%
Validation Cohort
Hospital mortality (n = 34) 3% 16% 33% 16% 26% 12% 52% 0% 24%
Percentage of total patients (n = 186) 36% 24% 40% 73% 27% 84% 16% 24% 76%
doi:10.1371/journal.pone.0070806.t006
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higher discrimination power, especially in the large sub-group of
patients allocated into the ward (0.84 vs 0.78).
Another study [21] has also compared the performance of
another PIRO score [11] with APACHE II [14] and MEDS [22]
scores in patients admitted into the emergency department with
criteria for early goal directed therapy and the severe sepsis
resuscitation bundle (that is patients with severe sepsis) and found
that for this group of patients, the discrimination power of PIRO
and APACHE II (AU-ROC=0.71) was better than MEDS (AU-
ROC=0.63). The PIRO score proposed by us, presents an even
higher discrimination power (AU-ROC=0.85); however, it should
be noted that different populations are included in both studies,
but this staging system preformed equally well in more severe
populations as it will be discussed later. Four clinical stages of
increased risk of hospital mortality were reached, based on ‘‘P’’
characteristics: age, gender, previous antibiotic therapy, chronic
hepatic disease, chronic hematologic disease, cancer, atheroscle-
rosis and a Karnofsky index,70; ‘‘I’’: type of infection; ‘‘R’’:
abnormal temperature, tachypnea, hyperglycemia, and the
severity of infection and ‘‘O’’: hypotension and a SOFA score$1.
The validation cohort comprised more severe patients, which
can perhaps be explained by seasonal variation, as it included
patients admitted in the winter, a period coincident to higher
occupation rates of hospital beds with more unscheduled
admissions. The higher severity of the patients included in the
validation cohort is probably the explanation for the higher
mortality rate observed. Nonetheless, even in this cohort of more
severe patients, the clinical staging system performed equally well,
which is a good indication of the generalizability of the model.
Many interventions tested in clinical trials of critically ill patients
with severe sepsis have failed to show benefit. One of the potential
reasons for this was an inadequate, non-specific selection of
patients enrolled in those trials relying mostly on the original
systemic inflammatory response syndrome (SIRS) criteria, with
equal weight being given to all variables. A clinical staging system
derived from a prognostic model, attributing different weights to
Table 7. Clinical staging system for hospital mortality in patients with infection according to the total score in each PIRO
component in the derivation cohort (n = 1035).
Stage I (n =436) Stage II (n = 354) Stage III (n = 197) Stage IV (n=42)
Predicted hospital mortality
rate 0%–5%
Predicted hospital mortality
rate 6%–20%
Predicted hospital mortality
rate 21%–50%
Predicted hospital mortality
rate 51%–100%
P1–2 I1–2 R1 O1 P1 I2 R1 O2 P3 I1–2 R1 O2 P2–3 I1–2 R2 O2
P1 I1 R1 O2 P1 I1 R2 O2
P2 I122 R1 O2
P3 I122 R1 O1
Observed hospital mortality rate = 2%
(CI95%=0.4–3%)
Observed hospital mortality rate = 11%
(CI95% = 8–15%)
Observed hospital mortality rate = 31%
(CI95% = 25–37%)
Observed hospital mortality rate = 71%
(CI95%=58–85%)
Only states with more than 5 patients were included in the different stages. CI – confidence interval.
doi:10.1371/journal.pone.0070806.t007
Figure 2. Different stages of PIRO obtained according to the different combinations of Predisposition (P1, P2, P3), Insult (I1, I2),
Response (R1, R2) and Organ dysfunction scores (O1, O2). The numbers represent the mortality rate for each state, e.g., the state P1I1R2O2 had
a mortality of 19% in the derivation cohort and 14% in the derivation cohort. Only states with more than 5 patients were considered. The dashes (2)
indicate that there was not enough patients in the respective state to evaluate mortality.
doi:10.1371/journal.pone.0070806.g002
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each co-variable of the four PIRO components, is more likely to
better stratify patients and refine inclusion criteria in such trials.
Previous studies have been limited to selected populations or
hospital settings [5,7–11]. Lisboa et al [7] developed a score
derived from the PIRO concept to predict ICU mortality in
patients with ventilator-associated pneumonia. Rello et al [8],
performed a similar study focused only on community acquired
pneumonia requiring ICU admission. The present study enriches
previous findings by including the three most frequent focus of
infection which leads to patients requiring hospital care.
Howell et al [10] developed a scoring system on patients
admitted to the emergency department with suspected infection.
However, they did not follow subsequent information from the
hospital course, so patients ultimately found to have a non-
infectious diagnosis may have been included. The only inclusion
criteria in the present study was the presence of clinical infection,
assessed by the CDC definitions [12] which can be done
immediately at bed side, thus not delaying patient stratification
and its adequate application in the current study was reinforced by
the high microbiological documentation rate, minimizing selection
bias.
Moreno et al [9] developed a score in ICU patients, from a
subset of patients from the SAPS III database, using a modified
definition of PIRO (PIR). They excluded patients who died during
the first 48 h, which might exclude patients with high response
and organ dysfunction scores (like septic shock), thus under-
weighting these components in their model. Besides including all
patients regardless of the severity of infection, the present study
evolves further into a clinical staging system.
Rubulotta et al [11] also performed a secondary analysis of two
cohorts of ICU patients (PROWESS and PROGRESS databases)
and defined a basic phenotypic characterization of patients
admitted with severe sepsis. However, in their retrospective study
it was not possible to analyze all variables originally proposed [2].
Being prospective and following a rigorous methodology, includ-
ing a large cohort of unselected hospitalized patients with
infection, the present study has reached a pilot clinical staging
system that might include all clinical relevant variables.
Classification trees were used to optimize the discrimination
ability of the model rather than determine cut-offs heuristically
after a logistic regression. Finally an independent validation cohort
was used to assess the robustness of the data and over fitting of the
derived model.
Although proponents of the PIRO staging system suggested
including biomarkers and/or variables reflecting genetic predis-
position, these tools are not yet widely or routinely available. Thus,
analyses were derived from covariates currently available at
bedside, which might help immediate patient management. Data
on microbiology documentation and antibiotics appropriateness
were also not included, although they could represent major
prognostic factors, they are not readily available for early
stratification, which is the main goal of the proposed staging
system.
The differences in mortality rates between the cohorts can be
explained by random variability due to the small sample size of the
validation cohort. However, this is a single-center study with a
limited number of patients, both in the derivation and in the
validation cohorts; nonetheless, it might represent a major step
forward in the clinical application of the PIRO concept,
expanding its applicability to all hospitalized patients with
infection. Further validation in different settings is needed.
In conclusion, it enriches the findings of previous studies by
reaching a clinical staging system through its prospective designed
with consideration of all proposed variables [2], including patients
at various levels of care inside the hospital, with different focus of
infection and severity of disease, widening its application to the
vast majority of infected patients, with a robust behavior both in
the derivation (AU-ROC=0.85) and in the validation cohort (AU-
ROC=0.84).
At this point, we propose its use mainly after further validation,
for early stratification and inclusion in clinical trials. We hope that
in the very near future, it can also be useful to tailor individual
therapy.
Conclusions
This study proposes a clinical staging system according to the
PIRO concept, with stratification of patients according to their risk
of death, derived from different scores obtained in Predisposition
considering: age, sex, previous antibiotic therapy, chronic hepatic
disease, chronic hematologic disease, cancer, atherosclerosis and a
Karnofsky index,70; type of infection in Insult/Infection;
abnormal temperature, tachypnea, hyperglycemia and severity of
infection in Response and hypotension and SOFA score$1 in
Organ dysfunction. It allowed the building of four stages with
increased risk of mortality: from stage I [i.e., P1I1R1O1] associated
with a low (#5%) risk of death, to stage IV [i.e., P3I2R2O2], where
the risk of mortality is highest (.50%).
Staging infected patients according to the four components of
the PIRO system may be a practical and relevant tool in sepsis
research. In particular, this new clinical staging system for hospital
mortality in patients with infection may prove to become a useful
triage tool to design individualized management strategies as well
as for refining inclusion criteria in clinical trials.
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